Esperion Therapeutis.Inc. buy F1Trader
Summary
This prediction ended on 02.02.21 with a price of €28.06. The price of Esperion Therapeutis.Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -17.45%. F1Trader has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Esperion Therapeutis.Inc. | -1.357% | -1.357% | 28.919% | -85.349% |
iShares Core DAX® | 1.510% | 2.268% | 18.541% | 18.577% |
iShares Nasdaq 100 | -0.271% | -1.533% | 22.755% | 34.901% |
iShares Nikkei 225® | -0.108% | 0.411% | 10.352% | -0.876% |
iShares S&P 500 | 0.479% | 0.563% | 22.881% | 38.847% |
Comments by F1Trader for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren